Cargando…

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

BACKGROUND: The role of tumour infiltrating lymphocytes (TILs) as a biomarker in non-invasive breast cancer is unclear. This meta-analysis assessed the prognostic impact of TIL levels in patients with non-invasive breast cancer. METHODS: Systematic literature search was performed to identify studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caparica, Rafael, Bruzzone, Marco, Agostinetto, Elisa, Franzoi, Maria Alice, Ceppi, Marcello, Radosevic-Robin, Nina, Penault-Llorca, Frédérique, Willard-Gallo, Karen, Loi, Sherene, Salgado, Roberto, de Azambuja, Evandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319525/ https://www.ncbi.nlm.nih.gov/pubmed/34273666 http://dx.doi.org/10.1016/j.breast.2021.07.007

Ejemplares similares

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ
por: Beguinot, Marie, et al.
Publicado: (2018)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
por: Caparica, R., et al.
Publicado: (2021)

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
por: Agostinetto, E., et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
por: Loi, Sherene
Publicado: (2013)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
por: Tagliamento, Marco, et al.
Publicado: (2021)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients
por: Lusho, Sejdi, et al.
Publicado: (2021)

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
por: Wein, Lironne, et al.
Publicado: (2017)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Relevance of tumor-infiltrating lymphocytes in breast cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2015)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
por: Nader-Marta, G., et al.
Publicado: (2022)

BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells
por: Privat, Maud, et al.
Publicado: (2014)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer
por: Rohan, Thomas E., et al.
Publicado: (2021)

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer
por: Jimeno, Rebeca, et al.
Publicado: (2022)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
por: Molinelli, C., et al.
Publicado: (2023)

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
por: Iacovazzo, Donato, et al.
Publicado: (2019)

S47. Tumour infiltrating lymphocytes - a predictive marker?
por: Galon, J
Publicado: (2014)

Tumour-infiltrating lymphocytes: from prognosis to treatment selection
por: Brummel, Koen, et al.
Publicado: (2022)

Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
por: Naghavian, Reza, et al.
Publicado: (2023)

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model
por: Satooka, Hiroki, et al.
Publicado: (2020)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
por: Loi, Sherene, et al.
Publicado: (2022)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
por: Poggio, Francesca, et al.
Publicado: (2018)

Immune Infiltration in Invasive Lobular Breast Cancer
por: Desmedt, Christine, et al.
Publicado: (2018)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
por: Franzoi, Maria Alice, et al.
Publicado: (2021)

PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer
por: Lusho, Sejdi, et al.
Publicado: (2020)

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers
por: Machiels, Melanie, et al.
Publicado: (2023)

Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.
por: Trentin, L., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_f5te02tr3on4au8eergvq94qip